GleamWall
中文EN

TXG 10x Genomics, Inc.

Laboratory Analytical Instruments · Nasdaq · SEC CIK 1770787 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-3.6%
TTM net income YoY12.1%
TTM EPS YoY17.5%
Revenue 3-yr CAGR1.5%
Net income 3-yr CAGR—

Margins

Gross margin71.9%
Operating margin-11.7%
Net margin-10.8%
FCF margin15.2%
EBITDA margin-5.3%

Returns

ROE-8.3%
ROA-6.4%
ROIC (approx.)-17.2%
Asset turnover0.59x

Leverage & solvency

Liabilities / assets21.2%
Debt / equity0.00x
Current ratio5.12x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-1.49x
Accruals ratio-16.0%
Payout ratio—
Capex / revenue1.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$150.67M$151.04M$150.84M$166.03M$149.00M$172.91M$154.88M$165.02M
Cost of revenue$37.74M$38.54M$44.66M$52.98M$48.70M$47.82M$49.44M$54.07M
Gross profit$112.93M$112.50M$106.18M$113.05M$100.31M$125.08M$105.44M$110.95M
R&D expense$52.93M$56.79M$56.85M$55.97M$57.19M$61.22M$64.25M$66.97M
SG&A expense$76.06M$78.66M$66.38M$76.62M$75.36M$74.43M$89.73M$93.83M
Operating income-$16.06M-$19.55M-$17.05M-$19.54M-$32.24M$30.13M-$39.33M-$49.84M
Interest expense$0$0—$0-$3,000$3,000$0$0
Pretax income-$18.48M-$18.64M-$12.85M-$15.19M-$28.20M$37.00M-$33.51M-$48.38M
Income tax$949,000-$714,000$623,000$1.06M-$733,000$2.46M$852,000$648,000
Net income-$19.43M-$17.93M-$13.47M-$16.25M-$27.47M$34.54M-$34.36M-$49.03M
EBITDA-$6.55M-$9.89M-$7.09M-$9.48M-$21.95M$37.94M-$31.31M-$41.09M
EPS (basic)-0.15-0.14-0.10—-0.220.28-0.28—
EPS (diluted)-0.15-0.14-0.10—-0.220.28-0.28—
Weighted avg. shares (diluted)130.81M129.98M128.29M—125.50M124.51M122.61M—
Balance sheet
Cash & equivalents$526.19M$502.51M$490.29M$473.97M$432.71M$397.71M$377.06M$344.07M
Short-term investments$49.49M$49.52M$49.56M$49.44M$49.58M$49.55M$49.84M$49.34M
Receivables$55.70M$47.55M$39.03M$47.01M$43.78M$49.98M$52.55M$87.86M
Inventory$64.63M$52.62M$53.49M$56.34M$61.96M$68.97M$74.71M$83.11M
Current assets$718.63M$674.67M$669.73M$684.45M$659.83M$655.66M$579.73M$584.39M
PP&E, net$210.24M$215.32M$220.59M$226.71M$232.53M$239.71M$246.09M$252.65M
Goodwill$6.92M$6.92M$4.51M$4.51M$4.51M$4.51M$4.51M$4.51M
Intangibles$58.66M$61.16M$59.91M$62.33M$64.76M$14.71M$15.19M$15.67M
Total assets$1.06B$1.03B$1.02B$1.04B$1.03B$979.97M$903.39M$918.64M
Current liabilities$140.37M$118.51M$113.60M$153.45M$147.32M$112.22M$107.90M$117.63M
Total liabilities$225.09M$204.52M$201.44M$245.04M$242.24M$206.69M$196.50M$208.50M
Shareholders' equity$838.04M$825.55M$814.32M$796.33M$785.12M$773.28M$706.89M$710.13M
Shares outstanding———127.69M———122.29M
Cash flow statement
Operating cash flow$15.83M$16.97M$26.12M$40.78M$43.21M$17.71M$34.35M-$6.75M
Capital expenditure$971,000$1.59M$1.60M$1.78M$687,000$1.58M$1.89M$2.72M
Free cash flow$14.86M$15.39M$24.52M$39.00M$42.53M$16.13M$32.46M-$9.46M
Investing cash flow-$503,000-$7.74M-$1.31M-$1.80M-$8.80M-$939,000-$1.89M-$51.59M
Financing cash flow$8.53M$3.02M-$8.42M$2.24M$617,000$3.52M$422,000$4.52M
Depreciation & amortization$9.50M$9.66M$9.96M$10.06M$10.30M$7.82M$8.02M$8.75M
Stock-based compensation$23.10M$25.62M$22.64M$25.22M$25.26M$27.25M$31.08M$32.54M

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.